BioSpace News Archive

Ardelyx, Inc. today announced that a New Drug Application (NDA) for tenapanor has been accepted for review by China’s Center for Drug Evaluation of the National Medical Products Administration (NMPA) for the control of serum phosphorus in adult patients with chronic kidney disease on hemodialysis.

ProSomnus, Inc., a leading CPAP alternative for the treatment of Obstructive Sleep Apnea, announced plans to design a head-to-head clinical trial comparing its precision oral appliance therapy and hypoglossal nerve stimulation in treating patients with severe OSA.

Labcorp (NYSE: LH), a global leader in innovative and comprehensive laboratory services, today announced the completion of the previously announced transaction that establishes a strategic relationship with Jefferson Health ( Jefferson ), the largest health system serving the greater Philadelphia and Southern New Jersey.

Elevation Oncology, Inc. announced today the appointment of Joseph Ferra , M.B.A., as its Chief Executive Officer.

Psycheceutical Bioscience, Inc today announced the first patient has been dosed in its Phase I study to evaluate its patented NeuroDirect™ ketamine topical delivery system for the treatment of Post Traumatic Stress Disorder (PTSD).

Molecular Templates, Inc. announced today it has entered into a definitive securities purchase agreement with certain healthcare investors that will provide up to $40 million in gross proceeds to MTEM through a private placement in two tranches.

Elixir Medical today announced enrollment completion in INFINITY-SWEDEHEART, a prospective, multicenter, single-blind, randomized clinical trial of the DynamX ® Coronary Bioadaptor System, the first metallic coronary artery implant that adapts to vessel physiology versus the Resolute Onyx™ Drug-Eluting Stent (DES).

To address challenges with error-prone, manual molecular testing workflows, Thermo Fisher Scientific today has introduced Diomni Enterprise Software, helping streamline routine diagnostics testing for standardization and faster time-to-results.

EarliTec Diagnostics, Inc. today announced U.S. Food and Drug Administration (FDA) 510(k) authorization of the second generation of its EarliPoint™ Evaluation for ASD for children ages 16-30 months old.

Mercury Bio has entered into a joint research, development, and licensing agreement with Old Bethpage, NY -based Himed.